Cellebrite DI Ltd. (CLBT) Spending and interest coverage
- R&D / revenue · 12 months: Value 23.94%; Formula and calculation Research and development expense / revenue. Period ending 2025-12-31..
- Stock-based compensation / revenue · 12 months: Value 9.44%; Formula and calculation Share-based compensation / revenue. Period ending 2025-12-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 23.94% | Research and development expense / revenue. Period ending 2025-12-31. $113.88M ÷ $475.68M × 100 ≈ 23.94% |
| Stock-based compensation / revenue · 12 months | 9.44% | Share-based compensation / revenue. Period ending 2025-12-31. $44.89M ÷ $475.68M × 100 ≈ 9.44% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 113.88M USD | Research and Development Expense |
| Revenue | 475.68M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 44.89M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 66.48M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $113.88M | $475.68M | $44.89M | $66.48M | (m) | 23.94% | 9.44% | (m) | (m) |
| 2025-06-30 | $107.41M | $436.73M | $35.91M | $61.86M | (m) | 24.59% | 8.22% | (m) | (m) |
| 2024-12-31 | $98.42M | $401.20M | $30.57M | $56.91M | (m) | 24.53% | 7.62% | (m) | (m) |
| 2024-06-30 | $89.09M | $412.53M | $22.19M | $50.21M | (m) | 21.60% | 5.38% | (m) | (m) |
| 2023-12-31 | $84.39M | $325.11M | $19.00M | $33.24M | (m) | 25.96% | 5.84% | (m) | (m) |
| 2023-06-30 | $83.55M | $298.14M | $16.30M | $13.35M | (m) | 28.02% | 5.47% | (m) | (m) |
| 2022-12-31 | $80.62M | $270.65M | $13.71M | $1.04M | (m) | 29.79% | 5.06% | (m) | (m) |
| 2022-06-30 | $74.51M | $257.79M | $9.54M | $-6.33M | (m) | 28.90% | 3.70% | (m) | (m) |
| 2021-12-31 | $65.54M | $246.25M | $6.48M | $13.82M | (m) | 26.62% | 2.63% | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $54.38M | $194.91M | $7.27M | $9.22M | (m) | 27.90% | 3.73% | (m) | (m) |
| 2019-12-31 | $46.57M | $171.85M | $12.76M | $-1.52M | (m) | 27.10% | 7.42% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.